… John Paolini, our Chief Medical Officer; and Eben … FDA granted KPL-387 Orphan Drug Designation for the treatment … drives collaboration expenses. ARCALYST collaboration profit grew a … Good day. Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA …

… Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines … of sites for, our clinical trials; delays or difficulty in …

… especially with its lead product ARCALYST for recurrent pericarditis. Looking forward … than nearly 90% of its biotechnology peers, suggesting the sector’s … toward sustainable earnings. Conclusion Kiniksa Pharmaceuticals represents the affordable growth model …

… the treatment of obesity. The trial demonstrated … biotechnology company that invents, develops, and commercializes life-transforming medicines … regeneron.com   christina.chan@regeneron.com       TABLE 1   REGENERON PHARMACEUTICALS … sales of ARCALYST®, which are …

… cross-trial comparisons, patients taking a 4-drug … first and only FDA-approved treatment for this debilitating … of profits from ARCALYST and higher royalty … disconnect. Follow Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Follow Regeneron Pharmaceuticals Inc. …

… July 29, 2025 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations … Phase III pivotal trial, supporting FDA approval of ARCALYST in recurrent … good persistence from the Medicare Part D patients who … efforts to shorten the treatment journey for patients by …

… Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines … , Evkeeza, Inmazeb Arcalyst and Zaltrap. The biotechnology company is expected to … sales of its key drug Eylea, amid increased competition …

… drug indication in the treatment of CAPS, making it the first approved medication … -rilonacept-regeneron-withdrawal- … ARCALYST [Rilonacept]. Available from: https://www.accessdata.fda.gov/drugsatfda … 35. Novartis Pharmaceuticals Corporation EH, NJ …

… ;3 clinical trial in recurrent … Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug … doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines … , our clinical trials; delays or …

… which is the only FDA-approved treatment for recurrent pericarditis to … federal changes to the Medicare Part D program, which … to pharmaceuticals, they would not impact ARCALYST supply received from Regeneron. That … we saw in the trials and what patients are …